• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Contribution of lowered hemoglobin threshold value in the diagnosis of polycythemia vera: Comparison of 2016 and 2008 WHO criteria.降低血红蛋白阈值在真性红细胞增多症诊断中的作用:2016 年和 2008 年 WHO 标准的比较。
Medicine (Baltimore). 2023 Aug 4;102(31):e34462. doi: 10.1097/MD.0000000000034462.
2
The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.世界卫生组织真性红细胞增多症诊断标准-红细胞质量与血红蛋白/红细胞压积水平和形态的关系。
Ann Hematol. 2018 Sep;97(9):1581-1590. doi: 10.1007/s00277-018-3344-3. Epub 2018 May 1.
3
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.2001年世界卫生组织以及更新后的欧洲关于费城染色体阴性慢性骨髓增殖性疾病的诊断、分类及分期的临床和病理标准。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754.
4
Inapparent polycythemia vera: an unrecognized diagnosis.隐匿性真性红细胞增多症:一种未被识别的诊断。
Am J Med. 1997 Jan;102(1):14-20. doi: 10.1016/s0002-9343(96)00351-8.
5
Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation.伴有JAK2外显子12突变的骨髓增殖性肿瘤的临床病理特征
Leuk Res. 2023 Apr;127:107033. doi: 10.1016/j.leukres.2023.107033. Epub 2023 Feb 8.
6
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].[BCR/ABL 阴性骨髓增殖性疾病的诊断与治疗——CZEMP 建议的原则与依据]
Vnitr Lek. 2011 Feb;57(2):189-213.
7
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.评估世界卫生组织诊断真性红细胞增多症的标准:一项前瞻性分析。
Blood. 2013 Sep 12;122(11):1881-6. doi: 10.1182/blood-2013-06-508416. Epub 2013 Jul 30.
8
Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.超越血红蛋白:何时以及如何检查可能的真性红细胞增多症
Clin Med Res. 2020 Mar;18(1):11-20. doi: 10.3121/cmr.2019.1483. Epub 2019 Oct 3.
9
The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.骨髓组织学在鉴别早期真性红细胞增多症和继发性(反应性)红细胞增多症中的价值。
Haematologica. 2001 Apr;86(4):368-74.
10
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病(MPD)、原发性血小板增多症(ET)、真性红细胞增多症(PV)和慢性特发性骨髓纤维化(CIMF)的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.

本文引用的文献

1
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.JAK2 未突变红细胞增多症:2023 年诊断与管理更新。
Am J Hematol. 2023 Jun;98(6):965-981. doi: 10.1002/ajh.26920. Epub 2023 Apr 3.
2
Secondary erythrocytosis.继发性红细胞增多症。
Expert Rev Hematol. 2023 Apr;16(4):245-251. doi: 10.1080/17474086.2023.2192475. Epub 2023 Mar 23.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版:髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
4
Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis.诊断标准代码区分真性红细胞增多症和继发性红细胞增多症的潜在局限性。
Sci Rep. 2022 Mar 18;12(1):4674. doi: 10.1038/s41598-022-08606-1.
5
Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.变异信号:慢性骨髓增殖性肿瘤的遗传、血液学和免疫学意义。
Biomolecules. 2022 Feb 11;12(2):291. doi: 10.3390/biom12020291.
6
Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.JAK2V617F 体细胞突变导致骨髓增殖性肿瘤不同表型的潜在机制研究进展。
Int J Mol Sci. 2022 Jan 18;23(3):1013. doi: 10.3390/ijms23031013.
7
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.真性红细胞增多症:历史的忽视、诊断的细节和治疗的观点。
Leukemia. 2021 Dec;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. Epub 2021 Sep 3.
8
How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey.2016年世界卫生组织真性红细胞增多症标准如何应用于我们的日常实践?来自土耳其的单中心研究。
Int J Hematol Oncol Stem Cell Res. 2020 Oct 1;14(4):232-236. doi: 10.18502/ijhoscr.v14i4.4478.
9
Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.一般人群中的红细胞增多症:临床特征及与克隆性造血的关系。
Blood Adv. 2020 Dec 22;4(24):6353-6363. doi: 10.1182/bloodadvances.2020003323.
10
Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes.真性红细胞增多症相关并发症:发病机制、临床表现及对预后的影响
J Blood Med. 2019 Oct 18;10:359-371. doi: 10.2147/JBM.S189922. eCollection 2019.

降低血红蛋白阈值在真性红细胞增多症诊断中的作用:2016 年和 2008 年 WHO 标准的比较。

Contribution of lowered hemoglobin threshold value in the diagnosis of polycythemia vera: Comparison of 2016 and 2008 WHO criteria.

机构信息

Department of Hematology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Department of Internal Medicine, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

出版信息

Medicine (Baltimore). 2023 Aug 4;102(31):e34462. doi: 10.1097/MD.0000000000034462.

DOI:10.1097/MD.0000000000034462
PMID:37543796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10403029/
Abstract

Polycythemia vera (PV) diagnosis remains a difficult task despite various updates in the 2016 World Health Organization (WHO) diagnostic criteria compared to 2008 criteria. This study aimed to examine the biochemical and clinical features of patients diagnosed with PV using the WHO 2016 criteria but would have been missed by the WHO 2008 criteria, and to ascertain the impact of the lowered thresholds on PV diagnosis. A total of 229 patients with suspected myeloproliferative neoplasms were included in this cross sectional study. The study group was divided with regard to hemoglobin values. Group A consisted of 126 patients with hemoglobin values of ≤ 18.5 g/dL in males and ≤ 16.5 g/dL in females. Group B comprised 103 patients with hemoglobin values of > 18.5 g/dL in males and > 16.5 g/dL in females. The number of PV diagnoses increased to 145 from 87 (increased by 66.67%) when the 2016 diagnostic criteria were employed rather that the 2008 criteria. Mean age and the frequency of female subjects were lower in Group A compared to Group B. The groups were similar in terms of chronic obstructive pulmonary disease/obstructive sleep apnea syndrome, spleen status, smoking status, and mean corpuscular volume, white blood count, neutrophil, eosinophil and platelet values. red blood cells and lactate dehydrogenase values were significantly higher, while lymphocyte counts were significantly lower in Group B. With the introduction of WHO 2016 criteria, we found a significant increase in the number of patients who were candidates for PV testing and were ultimately diagnosed with PV. These findings support the diagnostic value of the 2016 WHO criteria, and by extension, the lowered thresholds for detection of patients requiring further analysis.

摘要

真性红细胞增多症 (PV) 的诊断仍然是一项艰巨的任务,尽管与 2008 年标准相比,2016 年世界卫生组织 (WHO) 诊断标准已经进行了各种更新。本研究旨在检查使用 WHO 2016 标准诊断但可能被 WHO 2008 标准遗漏的 PV 患者的生化和临床特征,并确定降低阈值对 PV 诊断的影响。共有 229 名疑似骨髓增殖性肿瘤患者纳入本横断面研究。根据血红蛋白值将研究组分为两组。A 组包括 126 名男性血红蛋白值≤18.5 g/dL 和女性血红蛋白值≤16.5 g/dL 的患者。B 组包括 103 名男性血红蛋白值>18.5 g/dL 和女性血红蛋白值>16.5 g/dL 的患者。与 2008 年标准相比,当使用 2016 年诊断标准时,PV 诊断数量从 87 例增加到 145 例(增加了 66.67%)。与 B 组相比,A 组的平均年龄和女性患者比例较低。两组在慢性阻塞性肺疾病/阻塞性睡眠呼吸暂停综合征、脾脏状况、吸烟状况以及平均红细胞体积、白细胞计数、中性粒细胞、嗜酸性粒细胞和血小板值方面相似。红细胞和乳酸脱氢酶值明显较高,而淋巴细胞计数明显较低。随着 WHO 2016 标准的引入,我们发现有更多的患者适合进行 PV 检测,并最终被诊断为 PV。这些发现支持 2016 年 WHO 标准的诊断价值,进而支持降低检测需要进一步分析的患者的阈值。